Last-Chance access: experimental eye treatment opens for 75 RP patients
NCT ID NCT06574997
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This program offers an experimental treatment called OCU400 to up to 75 adults with retinitis pigmentosa (RP) who cannot join the main Phase 3 study. Participants must be 18 or older, have a confirmed genetic diagnosis of RP (except a specific mutation), and have remaining light-sensing cells in the eye. The goal is to provide access when no approved alternative is available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Research
Deerfield Beach, Florida, 33064, United States
-
Associated Retina Consultants
Phoenix, Arizona, 85020, United States
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Gundersen Health
La Crosse, Wisconsin, 54601, United States
-
Valley Retina Institute
McAllen, Texas, 78503, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single eye injection restore sight in genetic blindness?
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Stem cell eye transplant aims to halt blindness from rare genetic disease
- Could stem cells restore sight in damaged eyes?
- Gene therapy injection aims to restore sight in rare blindness
- Ground-Level vision test could help retinitis pigmentosa patients walk better